AbCellera Biologics (ABCL) Consolidated Net Income: 2019-2024
Historic Consolidated Net Income for AbCellera Biologics (ABCL) over the last 6 years, with Dec 2024 value amounting to -$162.9 million.
- AbCellera Biologics' Consolidated Net Income fell 57.73% to -$47.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$146.4 million, marking a year-over-year decrease of 192.35%. This contributed to the annual value of -$162.9 million for FY2024, which is 11.24% down from last year.
- Latest data reveals that AbCellera Biologics reported Consolidated Net Income of -$162.9 million as of FY2024, which was down 11.24% from -$146.4 million recorded in FY2023.
- AbCellera Biologics' 5-year Consolidated Net Income high stood at $158.5 million for FY2022, and its period low was -$162.9 million during FY2024.
- For the 3-year period, AbCellera Biologics' Consolidated Net Income averaged around -$50.2 million, with its median value being -$146.4 million (2023).
- As far as peak fluctuations go, AbCellera Biologics' Consolidated Net Income skyrocketed by 5,715.65% in 2020, and later crashed by 192.35% in 2023.
- Over the past 5 years, AbCellera Biologics' Consolidated Net Income (Yearly) stood at $124.2 million in 2020, then grew by 23.60% to $153.5 million in 2021, then rose by 3.29% to $158.5 million in 2022, then tumbled by 192.35% to -$146.4 million in 2023, then fell by 11.24% to -$162.9 million in 2024.